Based on the ALK-ABELLO AS DK -50 stock forecast from 0 analysts, the average analyst target price for ALK-ABELLO AS DK -50 is not available over the next 12 months. ALK-ABELLO AS DK -50’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ALK-ABELLO AS DK -50 is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, ALK-ABELLO AS DK -50’s stock price was EUR 21.36. ALK-ABELLO AS DK -50’s stock price has changed by +5.22% over the past week, +0.95% over the past month and +63.05% over the last year.
No recent analyst target price found for ALK-ABELLO AS DK -50
No recent average analyst rating found for ALK-ABELLO AS DK -50
Company Overview ALK-ABELLO AS DK -50
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark. Read Less
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic a...Read More
Frequently Asked Questions About ALK-ABELLO AS DK -50 (4AJ0:F) Stock
Stock Target Advisor's fundamental analysis for ALK-ABELLO AS DK -50's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4AJ0:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4AJ0:F's stock to indicate what its average analyst target is.
4AJ0:F stock's Price/Earning ratio is 46.13.
Our analysis grades 4AJ0:F stock's Price / Earning ratio at F. This means that 4AJ0:F stock's Price/Earning ratio is above 74% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4AJ0:F may be a overvalued for its sector.
The last closing price of 4AJ0:F's stock was EUR 21.36.
The most recent market capitalization for 4AJ0:F is EUR 4.78B.
Unfortunately we do not have enough analyst data on 4AJ0:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ALK-ABELLO AS DK -50's stock.
As per our most recent records ALK-ABELLO AS DK -50 has 2,806 Employees.
ALK-ABELLO AS DK -50's registered address is BOege AllE 6-8, Horsholm, Denmark, 2970.
You can get more information about it from ALK-ABELLO AS DK -50's website at https://www.alk.net.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ALK-ABELLO AS DK -50 (4AJ0:F) Stock
Stock Target Advisor's fundamental analysis for ALK-ABELLO AS DK -50's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4AJ0:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4AJ0:F's stock to indicate what its average analyst target is.
4AJ0:F stock's Price/Earning ratio is 46.13.
Our analysis grades 4AJ0:F stock's Price / Earning ratio at F. This means that 4AJ0:F stock's Price/Earning ratio is above 74% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4AJ0:F may be a overvalued for its sector.
The last closing price of 4AJ0:F's stock was EUR 21.36.
The most recent market capitalization for 4AJ0:F is EUR 4.78B.
Unfortunately we do not have enough analyst data on 4AJ0:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ALK-ABELLO AS DK -50's stock.
As per our most recent records ALK-ABELLO AS DK -50 has 2,806 Employees.
ALK-ABELLO AS DK -50's registered address is BOege AllE 6-8, Horsholm, Denmark, 2970.
You can get more information about it from ALK-ABELLO AS DK -50's website at https://www.alk.net.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4AJ0:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
